CCL20 and breast carcinoma: More interestingly, in the cohort of human epidermal receptor 2 (HER2)-negative breast cancer cases including TNBC or non-TNBC, after neoadjuvant taxane-containing chemotherapy, the patients with high CCL20 level were in a poor condition of relapse-free survival (RFS), and the higher the grade, the poorer the 5-year RFS in breast cancer patients with high CCL20 expression after NAC containing taxane (Fig 7B), which revealed that CCL20 played a vital role in influencing patient survival after taxane treatment not only in TNBC but also probably in non-TNBC.